Sepracor - Journal Publications: XOPENEX® (levalbuterol)

1. Ozminkowski RJ, Wang S, Long SR. The impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in Medicaid plans. Dis Manage Health Outcomes 2007;15(1):41-55.

2. Raissy HH, Harkins M, Esparham A, Kelly HW. Comparison of the dose response to levalbuterol with and without pretreatment with s-albuterol after methacholine-induced bronchoconstriction. Pharmacotherapy 2007;27(9):1231-1236.

2006 XOPENEX (levalbuterol) Publications

1. Berger WE, Milgrom H, Skoner DP, Tripp K, Parsey MV, Baumgartner RA, Xopenex Pediatric Asthma Group. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. CMRO 2006;22(6):1217-1226.

2. Chorley BN, Li Y, Fang S, Park JA, Adler KB. (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS. Am J Respir Cell Mol Biol 2006 January;34(1):119-27.

3. Donohue JF, Parsey, MV, Andrews C, D'Urzo T, Sharma S, Schaefer K, Claus R, Baumgartner RA, Levalbuterol COPD Study Group. Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. COPD: The Journal of Chronic Obstructive Pulmonary Disease 2006; In press.

4. Harris MB, Lewis ER, Mazumder S, Akhmedov A, Factor P. Differential effects of r-, s- and rs-albuterol on alveolar epithelial cell b2-adrenergic receptor function and alveolar fluid clearance in miceb. Proceedings of the American Thoracic Society 2006;3:A762.

5. Ibe BO, Portugal AM, Raj JU. Levalbuterol inhibits human airway smooth muscle cell proliferation: therapeutic implications in the management of asthma. Int Arch Allergy Immunol 2006;139(3):225-236.

6. Nowak R, Emerman C, Hanrahan JP et al. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006 May;24(3):259-67.

7. O'Riordan TG, Mao W, Palmer LB, Chen JJ. Assessing the effects of racemic and single-enantiomer albuterol on airway secretions in long-term intubated patients. CHEST 2006 January;129(1):124-32.

2005 XOPENEX (levalbuterol) Publications

1. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of β-agonists in human airway smooth muscle. JACI 2005, 116(1):65-72.

2. Auais A, Wedde-Beer K, Piedimonte G. Anti-inflammatory effect of albuterol enantiomers during respiratory syncytial virus infection in rats. Pediatric Pulmonology 2005; 40(3):228-234.

3. Hardasmalani MD, DeBari V, Bithoney Wg, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005 July;21(7):415-419.

4. Qureshi F, Zaritsky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005: 46(1):29-36.

5. Ralston ME, Euwema MS, Knecht KR, Ziolkowski TJ, Coakley TA, Cline SM. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005 July;29(1):29-35.

6. Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med 2005 November;23(7):842-847.

7. Skoner DP, Greos LS, Kim KT, et al. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pulmonol 2005;40:477-486.

2004 XOPENEX (levalbuterol) Publications

1. Abraha D, Cho SH, Agrawal DK, Park JM, Oh CK. (S,S)-formoterol increases the production of IL-4 in mast cells and the airways of a murine asthma model. Int Arch Allergy Immunol 2004; 133:380-388.

2. Agrawal DK, Anyurathna K, Kelbe P. (S)-albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004;113:503-510.

3. Berger WE, Ames DE, Harrison D. A patient satisfaction survey comparing levalbuterol with racemic albuterol in children. Allergy and Asthma Proc. 2004, 25:437-444.

4. D'Alonzo GA. Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease. JAOA 2004, 104(7):288-293.

5. Grogan D, Schaefer K, Varga J. Levalbuterol (LEV) results in greater patient and physician preference, symptom improvement and fewer side effects than racemic albuterol (RAC) in a 12-week study in patients with asthma or COPD. Presented at the Annual Meeting of the Southwest Allergy Forum, 2004. Puerta Vallarta, Mexico.

6. MacIntyre NR, Jr. Chronic obstructive pulmonary disease. Pharmacotherapy 2004; 24(5)Suppl:33s-43s.

7. McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004 June;38(6):967-972.

8. Nowak R, Emerman C, Schaefer K, Disantostefano R, Vaickus L, Roach J. Levalbuterol Compared with Racemic Albuterol in the Treatment of Acute Asthma: Results of a Pilot Study. AJEM. 2004;22:29-36.

9. Pleasants RA. Focus on short-acting β2-agonists: efficacy, safety, and patient preference. Pharmacotherapy 2004:24(5)Suppl:44s-53s.

10. Pleskow WW, Nelson HS, Schaefer K, Claus R, Roach J. Levalbuterol (LEV) shows enhanced clinical benefit over racemic albuterol (RAC). Annals of Allergy, Asthma, and Immunology 2004;92(1):111-2.

11. Pleskow WW, Nelson HS, Roach J, Schaefer K, Claus R, Koester, J. Levalbuterol (LEV) provides greater clinical benefit over racemic albuterol (RAC) in a 4-week study in patients with moderate-to-severe asthma. Presented at the Annual Meeting of the Southwest Allergy Forum 2004. Puerta Vallarta, Mexico.

12. Pleskow WW, Nelson HS, Schaefer K, Claus R, Roach JM. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy and Asthma Proc. 2004, 25:429-436.

13. Quinn C. The cost effectiveness of levalbuterol vs racemic albuterol. AJMC 2004, 10(5)Suppl: s153-s157.

14. Schoening SK. Management and treatment of reversible airway disease. AJMC 2004, 10(5)Suppl:s127-s128.

15. Schoening SK. Issues and challenges for managed care in the treatment of asthma and chronic obstructive pulmonary disease. AJMC 2004, 10(5)Suppl:s158-s163.

16. Shrepnek GH, Shrepnek SV. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. AJMC 2004, 10(5)Suppl: s129-s138.

17. Shrepnek GH, Shrepnek SV. An assessment of therapeutic regimens in the treatment of acute exacerbations in chronic obstructive pulmonary disease and asthma. AJMC 2004, 10(5)Suppl:s139-s152.

18. Szefler SJ. Current concepts in asthma treatment in children. Current Opinion in Pediatrics 2004;16(3):299-304.

19. Thompson M, Wise S, Rodenberg H. A preliminary comparison of levalbuterol and albuterol in prehospital care. J Emerg Med 2004 April;26(3):271-277.

20. Weinberger M. Is there any advantage to using levalbuterol in the treatment of asthma? Clinical Pulmonary Medicine 2004;11(3):129-134.

2003 XOPENEX (levalbuterol) Publications

1. Apter A.J. Clinical advances in adult asthma. Journal of Allergy and Clinical Immunology 2003;111(3 Suppl.):S780-S784.

2. Berger W. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Annals of Allergy, Asthma & Immunology. 2003;90:583-592.

3. Biswas AK, Fruedenthal WC. Levalbuterol toxicity: no reason to be jittery. European Respiratory Journal 2003 June;(6):1081.

4. Busse William W, Rosenwasser Lanny J. Mechanisms of asthma. Journal of Allergy and Clinical Immunology 2003;111(3 Suppl.):S799-804.

5. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 2003;143:731-6.

6. Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. CHEST 2003 September;124(3):844-849.

7. Lam S, Chen J. Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients. Am J Health Syst Pharm 2003 October 1;60(19):1971-1975.

8. Lemanske Jr. R.F., Busse W.W. Asthma Journal of Allergy and Clinical Immunology 2003;111 (2 Suppl. 2):S502-S519.

9. Liu A.H., Szefler S.J. Advances in childhood asthma: Hygiene hypothesis, natural history, and management. Journal of Allergy and Clinical Immunology 2003;111(3 Suppl.):S785-S792.

10. Manda W, Rennard S.I. Taking pharmacologic management of COPD into the future. Journal of Critical Illness 2003;18(1):33-42.

11. Naidu Sjosward Kerstin, Josefsson Martin, Ahlner Johan, Andersson Rolf G, Schmekel Birgitta. Metabolism of salbutamol differs between asthmatic patients and healthy volunteers. Pharmacology & Toxicology (Denmark) 2003; 92(1):27-32.

12. Nowak R. Single-isomer levalbuterol: a review of acute data. Current Allergy and Asthma Reports. 2003;3:172-178.

13. Roy Sitesh R, Milgrom Henry. Managing outpatient asthma exacerbations. Current Allergy and Asthma Reports 2003;3(2):179-89.

14. Roy SR, Milgrom H. Management of the acute exacerbation of asthma. Journal of Asthma 2003 September;(6):593-604.

15. Scott VL, Frazee LA. Retrospective comparison of nebulized levalbuterol and albuterol for adverse events in patients with acute airflow obstruction. Am J Ther 2003 September;10(5):341-347.

16. Sjosward Kerstin Naidu, Josefsson Martin, Ahlner Johan, Schmekel Birgitta. Preserved bronchial dilatation after salbutamol does not guarantee protection against bronchial hyperresponsiveness. Clinical Physiology and Functional Imaging (England) 2003;23(1):14-20. ISSN 1475-0961 Journal Code: 101137604.

17. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and pharmacoeconomic outcomes in patients hospitalized with chronic obstructive pulmonary disease or asthma. CHEST. 2003;123:128-35.

18. Truitt T, Witko J, Halpern M. Response to Letter to the Editor. CHEST. 2003;124:1176-7.

19. Varon J, Marik P.E. Managing acute severe asthma: What therapies to try, and when Journal of Respiratory Diseases 2003;24(2):67-76.

20. Wilmott RW. Single isomeric of albuterol-are there clinical benefits? J of Pediarics 2003;143:702.

2002 XOPENEX (levalbuterol) Publications

1. Asmus MJ, Hendeles L, Weinberger M, Ahrens RC, Bisgaard H, Lotvall J, O'Byrne P, Cockcroft D. Levalbuterol has not been established to have therapeutic advantages over racemic albuterol. JACI. 2002;110:325.

2. Baramki DF, Koester J, Anderson AJ, Borish LC. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: Anti-inflammatory influences of the (R)-isomer are negated in the presence of the (S)-isomer. J Allergy Clin Immunol. 2002;109:449-54.

3. Batra V, Niazi S, Peters S.P. Persistent asthma: What approach is best? Journal of Respiratory Diseases 2002;23(6):330-340.

4. Boulton DW, Fawcett JP. BetaSUB2-agonist eutomers: a rational option for the treatment of asthma? American Journal of Respiratory Medicine 2002;1(5):305-311.

5. Chowdhury BA. Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma. JACI. 2002;110:324-328.

6. Corcoran JA, Lee CK. Evaluation of appropriate use of levalbuterol following implementation of criteria for use. ASHP Midyear Clinical Meeting 2002;37(DEC):pP-478R.

7. Datta D, Lahiri B, ZuWallack R. A comparison of nebulized levalbuterol, albuterol, and combined albuterol and ipratropium in patients with stable COPD; preliminary observations. Euro Resp Soc Annu Congress 2002;P1593.

8. Dutta E.J, Li J T C. Beta-agonists. Med.Clin. North Am. 2002;86(5):991-1008.

9. Dyer N, Fisher. Vs epinephrine interaction with beta-blockers. Hospital Pharmacy 2002; 37(7):780-781,785

10. Emerman CL. Levalbuterol for treatment of acute asthma. Drug Benefit Trends 2002;14(2):33.

11. Flockhart D.A., Nelson H.S. Single isomer versus racemate: Is there a difference? Clinical comparisons in allergy and gastroenterology. CNS Spectrums 2002;7(4 Suppl. 1):23-27.

12. Frohock J, Wijkstrom-Frei C, Salathe M. Effects of albuterol enantiomers on ciliary beat frequency in ovine tracheal epithelial cells. J Appl Physiol. 2002;92:2396-2402.

13. Kelly H.W. Severe, acute asthma as therapeutic orphan. Annals of Pharmacotherapy 2002;6(7-8):287-1289.

14. Lam S, Chen J. Comparison of heart rate changes induced by nebulized racemic albuterol and levalbuterol in critically ill patients. Int Pharm Abs 2002;V37, (DEC), pP-346E.

15. Lenfant C. National asthma education and prevention program: Expert panel report. Guidelines for the diagnosis and management of asthma update on selected topics. Journal of Allergy and Clinical Immunology 2002;10(5 Suppl.):S141-S219.

16. Marik P.E., Varon J., Fromm Jr. R. The management of acute severe asthma. Journal of Emergency Medicine 2002;23(3):257-268.

17. Milgrom H, Skoner D, Bensch G, Kim K, Claus R, Baumgartner R. Reply to the letter to the editor. JACI 2002; 110:325.

18. Pinon M. Evaluation of therapeutically interchanging levalbuterol for racemic albuterol in a community hospital setting. ASHP Midyear Clinical Meeting 2002;37(DEC):pMCS-13.

19. Rodenberg H: Effect of levalbuterol on prehospital patient parameters. American Journal of Emergency Medicine 2002, 20:481-3

20. Rosenbaum J.F. Conclusion: The future of single-isomer pharmacology. CNS Spectrums 2002; 7(4 Suppl. 1):55.

21. Scarfone R.J., Friedlaender E.Y. BetaSUB2-agonists in acute asthma: The evolving state of the art. Pediatric Emergency Care 2002;18(6):442-447.

22. Shaw J.L., Zacharisen M.C., Levy M. Why is this patient not responding to asthma therapy? Journal of Respiratory Diseases 2002;23(10):503-505.

23. Shepherd J.M., Duddleston D.N., Hicks G.S., Low A.K., Russell L.D., Brown C.A. Asthma: A brief overview. American Journal of the Medical Sciences 2002;324(4):174-179.

24. Siwik J.P., Nowak R.M., Zoratti E.M. The evaluation and management of acute, severe asthma Medical Clinics of North America 2002;86(5):1049-1071.

25. Slattery D, Wong SW, Colin AA. Levalbuterol hydrochloride. Pediatr Pulmonol. 2002;33:151-7.

26. Streetman D.D., Bhatt Mehta V, Johnson C.E. Management of acute, severe asthma in children. Ann. Pharmacother. 2002;36(7-8):1249-60.

27. Tanaka L, El-Dahr J. Treatment of paradoxical bronchoconstriction in an asthmatic boy with levalbuterol HCl: a case report [abstract]. Annals of Allergy, Asthma, & Immunology 2002;88:97.

28. Thomas J.R., von Gunten C.F. Clinical management of dyspnoea. Lancet Oncology 2002; 3(4):223-228.

29. Xopenex. New asthma relief for kids. Nursing 2002;32(5):18.